Evolocumab , a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type @ ( PCSK@ ) , demonstrated marked reductions in plasma low-density lipoprotein cholesterol ( LDL-C ) in a phase @ study in statin-intolerant patients .